News – Page 1094 – Endpoints News

With help from J&J, upstart Provention lands rights to two mid-stage IBD drugs and shoots for PhII

8 years ago

Chris Garabedian's Xontogeny shepherds its first biotech through a $10M startup round

8 years ago

Want to start fixing the gender diversity problem in your biotech company? Put down the silver bullet

8 years ago

After settling with the SEC, biotech VC Steven Burrill now faces up to 30 years for fraud, tax evasion charges

8 years ago

FDA's Janet Woodcock: the clinical trials system is 'broken'

8 years ago

Arcus scores $305M regional development pact with Taiho; Shire, Shionogi tout PhIII ADHD study

8 years ago

Angry Pfizer accuses J&J of violating antitrust laws in safeguarding a megablockbuster franchise

8 years ago

Sanofi's Elias Zerhouni says his R&D group is ready to stand alone — but big M&A and partnerships still loom large

8 years ago

Lightstone crew adds a $250M Fund II with plans to back biotech startups

8 years ago

Tech maven Travis May takes the helm of Roivant's data mining startup

8 years ago

Alnylam achieves breakthrough RNAi success as PhIII patisiran study hits all goals, shares soar

8 years ago

From big biopharma to biotech CEO, John Houston’s R&D journey highlights a fast-changing world

8 years ago

Troubled Teva turns to risk-sharing team at Nuvelution to gamble on a new PhIII study

8 years ago

OptiNose files for $100M IPO; GSK wins three-in-one COPD OK

8 years ago

OncoMed chief Paul Hastings goes on medical leave

8 years ago

Highlighting a major shift at the FDA, regulators put Amicus' once-spurned drug on fast track

8 years ago

With CRO consolidation in full swing, Catalent inks a $950M deal to acquire Cook Pharmica and signals an appetite for ...

8 years ago

Atlas ramps up a new biotech player focused on neurology, with a $30M round to fund the work

8 years ago

Ex-GSK CEO, R&D chief Andrew Witty and Moncef Slaoui are jumping into the biotech VC game

8 years ago

AbbVie and Roche tout a positive PhIII combo study of Venclexta, Rituxan in CLL — ahead of FDA pitch

8 years ago

Avanir vet Keith Katkin takes charge at Urovant; Teva unloads assets while uploading new CEO

8 years ago

Harvard biotech wiz Greg Verdine grabs a $55M A round to build a groundbreaking biotech

8 years ago

Bidding war erupts over Dimension’s gene therapy pipeline as Ultragenyx counters Regenxbio deal

8 years ago

Shares rocket up as Nabriva Therapeutics touts a PhIII win for antibiotic

8 years ago

First page Previous page 1091 1092 109310941095 1096 1097 Next page Last page